Answers are grounded in this paper and cite their sources.
The development of spectral-domain optical coherence tomography (OCT) allows for the highest commercially available resolution of in vivo retinal anatomic details to date. The ability to see the macula with ever increasing detail is dramatically improving our understanding of the pathogenesis of retinal disease. However, the only prospective study that partially evaluated spectral-domain OCT versus time-domain OCT failed to show any clinical benefit of increased OCT resolution. Clinical outcomes, eg, best-corrected visual acuity, central macular thickness and number of injections, with "newer" OCT technologies remain an unproven advantage.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: